Abbott Laboratories (ABT) EBITDA (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of EBITDA data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 20.56% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $7.7 billion (up 8.03% YoY), and the FY2025 full-year result was $8.1 billion, up 17.99% from the prior year.
• EBITDA eased to $1.3 billion in Q1 2026, from $2.3 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• A 5-year average of $1.8 billion and a median of $1.8 billion in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 70.69% in 2022 and slumped 48.18% in 2023, its largest moves.
• Tracing ABT's EBITDA over 5 years: stood at $1.3 billion in 2022, then soared by 36.5% to $1.8 billion in 2023, then rose by 7.36% to $1.9 billion in 2024, then advanced by 17.79% to $2.3 billion in 2025, then sank by 40.25% to $1.3 billion in 2026.
• Business Quant data shows ABT's EBITDA at $1.3 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.1 billion in Q3 2025.